Pages that link to "Q36890181"

The following pages link to Valproic acid for the treatment of myeloid malignancies (Q36890181):

Displaying 49 items.

• Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents (Q24633763) (← links)
• Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy (Q28082536) (← links)
• Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia (Q28472176) (← links)
• Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells (Q28476348) (← links)
• Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2 phosphorylation (Q30495932) (← links)
• Differentiation therapy of leukemia: 3 decades of development (Q33409795) (← links)
• Integrating systems biology sources illuminates drug action (Q33645618) (← links)
• The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death (Q34662212) (← links)
• Valproic acid promotes radiosensitization in meningioma stem-like cells (Q35833208) (← links)
• Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid (Q36001895) (← links)
• Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells (Q36026945) (← links)
• Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro (Q36230522) (← links)
• Acetylation of histone deacetylase 1 regulates NuRD corepressor complex activity (Q36418796) (← links)
• Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review (Q37130104) (← links)
• Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias (Q37184917) (← links)
• A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer (Q37200466) (← links)
• Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. (Q37310619) (← links)
• Histone deacetylases and the immunological network: implications in cancer and inflammation (Q37621256) (← links)
• Histone Modification Therapy of Cancer (Q37797706) (← links)
• Vorinostat in acute myeloid leukemia and myelodysplastic syndromes (Q37824712) (← links)
• Evi1 forms a bridge between the epigenetic machinery and signaling pathways. (Q37906986) (← links)
• Influence of drugs on gap junctions in glioma cell lines and primary astrocytes in vitro (Q38218094) (← links)
• The myelodysplastic syndromes: the era of understanding (Q38245878) (← links)
• Synthesis, Characterization, and Anti-Cancer Activity of Some New N'-(2-Oxoindolin-3-ylidene)-2-propylpentane hydrazide-hydrazones Derivatives. (Q38546970) (← links)
• Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma (Q38996046) (← links)
• The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells (Q39064829) (← links)
• Mechanism of growth inhibition of prostate cancer xenografts by valproic acid (Q39254228) (← links)
• Valproic acid inhibits proliferation of EB virus-infected natural killer cells (Q39337509) (← links)
• Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi (Q39432616) (← links)
• Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells (Q39588189) (← links)
• Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation (Q39699250) (← links)
• The ATRA-induced differentiation of medulloblastoma cells is enhanced with LOX/COX inhibitors: an analysis of gene expression (Q40999604) (← links)
• The DAC system and associations with acute leukemias and myelodysplastic syndromes (Q41209862) (← links)
• Inhibition of Class II Histone Deacetylases in the Spinal Cord Attenuates Inflammatory Hyperalgesia (Q41964772) (← links)
• Sodium valproate inhibits the growth of human cholangiocarcinoma in vitro and in vivo (Q42734243) (← links)
• Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation (Q42739964) (← links)
• Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells (Q43269070) (← links)
• Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis (Q43285192) (← links)
• Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells (Q43290186) (← links)
• Enantioselective apoptosis induction in histiocytic lymphoma cells and acute promyelocytic leukemia cells (Q44152775) (← links)
• Individualized management and therapy of myelodysplastic syndromes (Q46261524) (← links)
• Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells (Q46375225) (← links)
• Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients (Q46397769) (← links)
• Valproic acid for the treatment of myeloid malignancies (Q46695518) (← links)
• In Vivo Chemical Screen in Zebrafish Embryos Identifies Regulators of Hematopoiesis Using a Semiautomated Imaging Assay (Q57532584) (← links)
• Valproic acid causes radiosensitivity of breast cancer cells disrupting the DNA repair pathway (Q64389971) (← links)
• Valproic acid affects the engraftment of TPO-expanded cord blood cells in NOD/SCID mice (Q82939042) (← links)
• Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C (Q83807467) (← links)
• Mild antagonistic effect of Valproic acid in combination with AZD2461 in MCF-7 breast cancer cells (Q92409051) (← links)